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Abstract
Human CD8
+ regulatory T cells, particularly the CD8
+CD28
2 T suppressor cells, have emerged as an important modulator of
alloimmunity. Understanding the conditions under which these cells are induced and/or expanded would greatly facilitate
their application in future clinical trials. In the current study, we develop a novel strategy that combines common gamma
chain (cc) cytokines IL-2, IL-7 and IL-15 and donor antigen presenting cells (APCs) to stimulate full HLA-mismatched
allogeneic human CD8
+ T cells which results in significant expansions of donor-specific CD8
+CD28
2 T suppressor cells in
vitro. The expanded CD8
+CD28
2 T cells exhibit increased expressions of CTLA-4, FoxP3, and CD25, while down-regulate
expressions of CD56, CD57, CD127, and perforin. Furthermore, these cells suppress proliferation of CD4
+ T cells in a contact-
dependent and cytokine-independent manner. Interestingly, the specificity of suppression is restricted by the donor HLA
class I antigens but promiscuous to HLA class II antigens, providing a potential mechanism for linked suppression. Taken
together, our results demonstrate a novel role for common cc cytokines in combination with donor APCs in the expansion
of donor-specific CD8
+CD28
2 T suppressor cells, and represent a robust strategy for in vitro generation of such cells for
adoptive cellular immunotherapy in transplantation.
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Introduction
Allogeneic organ transplantation has emerged as the current
best therapeutic option for selected patients with end stage organ
failure. Tolerance induction is highly desirable in this population,
because long-term immunosuppressive therapy is associated with
significant risks for opportunistic infections, degenerative and
metabolic diseases, as well as malignancies. Regulatory T cell
(Treg) based therapy has emerged as a promising means for
immunomodulation to achieve transplant tolerance. Great interest
has been focused on CD4
+ Tregs [1], and cell therapies using
adoptive transfer of in vitro generated CD4
+ Treg cells have
demonstrated promising efficacy for immunomodulation in animal
models of allogeneic transplantation as well as in clinical trials of
human allogeneic bone marrow transplantation for the control of
graft versus host disease [2,3,4]. However, evidence also suggests
that CD8
+ Tregs may play an important regulatory role in
transplant tolerance [5,6,7,8], in addition to possible immuno-
modulatory roles in autoimmune disorders [9,10], cancers [11]
and aging [12]. Several subsets of CD8
+ Tregs have been
observed. Natural CD8
+ Tregs have been reported to be
CD8
+CD25
+, CD8
+CD122
+, or CD8
+CXCR3
+ in different
systems [13,14,15]. Induced CD8
+ Tregs have also been reported
to bear various phenotypic characteristics, such as CD28
2,
CD56
+, CD57
+, CTLA4
+, CD103
+, CD25
+Foxp3
+ or
LAG3
+CCL4
+ [5,16,17,18,19]. These natural or induced CD8
+
Tregs exert their suppressive function by cell-cell contact [5] or by
producing soluble cytokines [15,17], and in some circumstances by
inducing tolerogenicity in antigen presenting cells (APCs) [20].
Among the various CD8
+ Tregs, CD8
+CD28
2 T suppressor
cells have emerged as an important modulator of alloimmunity.
Human allo-specific CD8
+CD28
2 cells have been shown to emerge
after repeated stimulation with allogeneic APCs with supplemental
recombinant human IL-2 in vitro [5]. These cells have subsequently
been termed ‘‘Ts cells’’. Similarly, autoantigen-specific CD8
+ Tregs
including CD8
+CD28
2 cells have been reported to be induced in
vitro via stimulation of peripheral T cells obtained from patients
with systemic lupus erythematosus (SLE) in the presence of a
combination of common gamma chain (cc) cytokines IL-2, IL-7
and IL-15 [21]. These conditions under which CD8
+CD28
2 cells
are induced are distinct from those in which CD4
+ Tregs are
induced, in that the latter frequently require the presence of
tolerance promoting agents such as TGF-b, IL-10, or rapamycin
in the culture [22,23,24,25]. While the mechanisms by which
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+CD28
2 cells are induced under such apparently non-
tolerance promoting conditions remain unclear, the induced
CD8
+CD28
2 cells nevertheless exhibit potent antigen-specific
suppressive capacities [5,21]. The cc cytokines have also been
reported to induce stable loss of CD28 expression in actively
dividing CD8
+CD28
+ T cells [26,27], thereby promoting the
generation of a preponderance of CD8
+CD28
2 T cells. We
therefore questioned if cc cytokines in combination with donor
APCs may be used to expand donor-specific CD8
+CD28
2 T
suppressor cells in large numbers in vitro, and if so, what the
mechanisms of donor-specific suppression are.
In this report, we utilized APCs and T cells variably matched
for human leukocyte antigen (HLA) class I or class II to study the
ability and mechanisms of suppression of the CD8
+CD28
2 T
cells generated in vitro by this novel approach of combining
allogeneic APCs plus cc cytokines. Our findings indicate that
large numbers of CD8
+CD28
2 T cells with potent donor-specific
suppressive capacity can be effectively generated in vitro using this
approach. Furthermore, their suppressive capacity is contact-
dependent and is restricted only by the donor HLA class I
antigens but promiscuous to HLA class II antigens. To our
knowledge, this is the first report demonstrating a role of
combination cc cytokines in the in vitro generation of large
numbers of human donor-specific CD8
+CD28
2 suppressor cells.
Findings from this study may have important implications for
designing future Treg based therapies for prevention of rejection
in human organ or tissue transplantation.
Results
Donor APCs plus cc cytokines induce rapid expansion of
CD8
+CD28
2 T cells in culture
The CD28
2 cell population accounts for a small fraction of
freshly isolated human CD8
+ T cells from PBMCs (5.5%,
Figure 1A, top panel, Day 0). Fresh CD8
+ T cells were stimulated
with HLA-A, -B and -DR complete-mismatched APCs in the
presence of IL-2 alone or a combination of cc cytokines IL-2, IL-7
and IL-15 as described in Materials and Methods [21]. As shown in
Figure 1A bottom panels (Day 6, Day 9), culture in the presence of
IL-2 alone allowed only minimal increase of the CD28
2
population over time. In contrast, culture in the presence of a
combination of cc cytokines IL-2, IL-7 and IL-15 significantly
increased this population from 5.5% of all CD8
+ cells on day 0 to
45.7% (51.5+/28.5%) on day 6, and 55.5% (58.5+/27.2%) on
day 9 (Figure 1A), likely representing down-regulation of cell
surface CD28 during the in vitro cell activation as previously
described [26,27]. The total number of CD8
+CD28
2 recovered at
the end of the 9 day culture increased by ,26.7+/27.5 fold
(Figure 1B). The most dramatic increase of this population was
observed when IL-15 was added to the culture, with moderate
effect observed with IL-7 on the expansion of this population (data
not shown).
In vitro expanded CD8
+CD28
2 T cells suppress CD4
+ T
cells proliferation in a donor-specific manner
CD8
+CD28
2 T cells were generated from individual A by
culturing with allogeneic APCs from individual B (designated as
B-APC) in the presence of the cc cytokine combination as described
above. After 9 days of culture, the resulting CD8
+CD28
2 T cells
were isolated (purity.95%) and used as suppressors (S) to test for
their suppressive capacity in mixed lymphocyte reactions (MLRs)
using CD4
+ T cells from individual A (designated as A-T4) as
responders (R). Suppressor to responder ratios (S:R) of 0.5:1, 0.1:1
and 0.02:1 were tested (with the cell number of ‘‘R’’ kept constant).
As shown in Figure 2A, when APCs from the original priming
stimulator (B-APC) were used as stimulators of the MLRs,
proliferation of A-T4 (measured by CFSE dilution) was markedly
suppressed in a dose-dependent manner by the in vitro expanded
CD8
+CD28
2 T cells. Suppression was also confirmed by using
3H-thymidine incorporation as a read-out (Figure 2B). In contrast,
when APCs from an HLA-A, -B and -DR mismatched indifferent
stimulator (I-APC) were used as stimulators of the MLRs,
CD8
+CD28
2 cells exhibited only marginal suppression at the
highest S:R ratio tested (0.5:1, shown in Fig. 2A, middle panels).
No suppression could be demonstrated when anti-CD3/CD28
coated Dynabeads were used for stimulating the CD4
+ T cells
(Figure 2A, bottom panels). Taken together, our results indicate
that the CD8
+CD28
2 T cell generated from donor APCs plus cc
cytokine-driven in vitro expansion suppress CD4
+ T cells
proliferation only in a donor-specific manner.
Suppression by the in vitro expanded CD8
+CD28
2 T cells
is restricted by donor HLA class I antigens but
promiscuous to HLA class II antigens
To determine whether the donor specificity observed in the
above suppression of proliferation was restricted via recognition of
HLA class I antigens only, we examined the ability of the
CD8
+CD28
2 T cells generated from culturing with B-APC to
suppress proliferation stimulated by APCs from a third-party
donor (C-APC) who shared identical HLA class I but not class II
antigens with individual B. The ability of suppressing C-APC driven
proliferation was compared with that of suppressing I-APC driven
proliferation (I-APC were from an indifferent individual who was
mismatched with individual A for both HLA class I and class II
antigens). Table 1 provides one example of the HLA class I and
class II antigen typing of individuals A, B, C, and I used for one of
three such experiments. As shown representatively in Figure 3,
proliferation of A-T4 was profoundly suppressed when B-APC was
used as the stimulator as expected. Interestingly, a significant
suppression was also observed, albeit at a slightly reduced level,
when C-APC was used as the stimulator. In contrast, suppression
was almost completely lost when I-APC was used as the stimulator.
These data support the hypothesis that suppression by the in vitro
expanded CD8
+CD28
2 T cells is mediated via specific interac-
tions between the T cell receptor (TCR) on the CD8
+ cells and
donor HLA class I molecules on the APCs, and such interactions
can lead to suppression of CD4
+ cells with TCRs specific for HLA
class II molecules co-expressed on the same interacting APCs (the
C-APC in this case) but different from those expressed on the
original priming APCs (the B-APC in this case). This finding
corroborates with the previous observation that CD8 suppressor
cells are capable of exerting linked suppression via interactions
with APCs [28].
Suppression by the in vitro expanded CD8
+CD28
2 T cells
is contact dependent but IFN-c or TGF-b independent
The role of cell-cell contact in suppression was examined using
transwell assays as shown in Figure 4A. The lower chamber was
plated with CFSE-labeled responder cells (R) and stimulator cells
(B-APC), and the in vitro expanded CD8
+CD28
2 T cells (S) were
added either in the lower chamber to allow cell-cell contact or in
the upper chamber to prevent cell-cell contact. As shown in
Figure 4A, suppression of proliferation by CD8
+CD28
2 T cells
was abolished when these cells were plated in the upper chamber
of the transwells, indicating that suppression by these cells requires
cell-cell contact between the CD8
+CD28
2 T cells, stimulator
APCs and/or the responder CD4
+ T cells. This finding is
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the suppressive activity of the in vitro expanded CD8
+CD28
2 T
cells observed in Figure 3.
Several reports have implicated TGF-b [13,29,30] and IFN-c
[8,31,32] in the mechanisms of regulation by CD8
+ suppressor
cells. To test for a potential role of TGF-b or IFN-c in the
Figure 1. Donor APCs plus cc cytokines induce rapid expansion of CD8
+CD28
2 T cells in culture. Freshly purified CD8
+ T cells (2610
6 per
well) from healthy volunteers were stimulated by HLA-A, B and DR mismatched allogeneic APCs (1610
6 per well) for 9 days in 24-well plates
supplemented with IL-2 alone or a combination of IL-2, IL-7 and IL-15. A, Expression of CD28 on CD8
+ cells over time. Histograms were gated on the
CD8
+ population. B, Expansion of cell numbers of the CD8
+CD28
2 population over time by donor APC plus cc cytokines stimulation. The numbers of
the CD8
+CD28
2 cells per well of 24-well culture plates were calculated for day 0, 6 and 9. Data shown in A are representative of three independent
experiments. Data shown in B is the average of three independent experiments.
doi:10.1371/journal.pone.0028948.g001
Figure 2. In vitro expanded CD8
+CD28
2 T cells suppress CD4
+ T cells proliferation in a donor-specific manner. CD8
+ T cells from donor
A were stimulated with APCs from donor B plus cc cytokines for 9 days, followed by enrichment of the CD8
+CD28
2 population as described in
Materials and Methods.5 610
4 CFSE labeled purified responder CD4
+ T cells (R) from donor A were stimulated with 5610
4 APCs from donor B (B-APC)
or from an indifferent donor (I-APC, HLA-A, B and DR fully mismatched with donor B), or 1610
4 anti-CD3/CD28 coated Dynabeads in triplicates in 96-
well plates. The in vitro expanded CD8
+CD28
2 T cells were added as putative suppressors (S) at S:R ratios of 0.5:1, 0.1:1 and 0.02:1 (with the cell
number of ‘‘R’’ kept constant). Proliferation of the CD4
+ cells was measured by CFSE dilution (A)o rb y
3H thymidine uptake (B). Data shown are
representative of three independent experiments. * P=0.002; ** P=0.009; *** P=0.008.
doi:10.1371/journal.pone.0028948.g002
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+CD28
2 T cells
in our system, anti-human IFN-c or anti-human TGF-b antibody
was added to the suppression assays described above (baseline
suppression without the blocking antibodies is shown in Figure 4B).
As shown in Figure 4C and Figure 4D, neither anti-IFN-c nor anti-
TGF-b antibodies at increasing concentrations affected suppres-
sion by CD8
+CD28
2 T cells.
In vitro expanded CD8
+CD28
2 T cells do not exhibit
cytotoxicity
To test whether cytotoxicity towards the stimulating APCs
contributes to the suppression of donor-specific proliferation
observed above, we assessed the cytotoxicity of CD8
+CD28
2 T
cells using a CFSE-based assay [33]. We designed this assay to
specifically determine the ability of the CD8
+CD28
2 T cells to lyse
allogeneic donor APCs used as stimulators in the above MLRs. In
this assay, ‘‘effector cells’’ were the CD8
+CD28
2 T cells generated
by the donor APC plus cc cytokine-driven in vitro cultures as
above. The CD8
+CD28
+ T cells generated by the same cultures
were used as control effector cells because of their known
cytotoxicity [5,34,35]. Target cells were either the original priming
APCs which were labeled with a high concentration of CFSE
(B-APC-CFSE
high), or control APCs from an HLA-A, -B, and -DR
mismatched indifferent individual which were labeled with a low
concentration of CFSE (I-APC-CFSE
low). A 1:1 mixture of I-APC-
CFSE
low and B-APC-CFSE
high cells were plated either by
themselves or with the same number of the putative
(CD8
+CD28
2) or control (CD8
+CD28
+) effector cells. At 24, 72,
and 120 hr of culture, cells were collected and analyzed by FACS
to enumerate CFSE
low and CFSE
high cells. The ratio of cell
numbers of I-APC-CFSE
low over B-APC-CFSE
high (shown as ‘‘R’’ in
Figure 5) over time provided a measure of specific cytolytic effect
of the putative effector cells on these two target populations. As
shown in Figure 5 left panels, minimal spontaneous lysis was
observed as the ratio R remained stable over time in the absence of
any effector cells. When the CD8
+CD28
+ T cells were added as
effector cells (Figure 5, middle panels), R increased to 1.5 at 72 hrs
and 2.9 at 120 hrs, demonstrating that B-APC-CFSE
high cells were
specifically killed by the CD8
+CD28
+ T cells. In contrast, when
the CD8
+CD28
2 T cells were added as effector cells, R remained
unchanged over time, indicating that the CD8
+CD28
2 T cells
exhibit no specific cytolysis towards the B-APC cells (Figure 5, right
panels).
Figure 3. Suppression by the in vitro expanded CD8
+CD28
2 T cells is restricted by donor HLA class I antigens. Suppression assays were
set up as described in Figure 2, with the exception that the stimulator APCs for CD4
+ proliferation were from either the priming donor (B-APC), an
indifferent donor (I-APC, HLA-A, B and DR fully mismatched with donor B), or a partially matched donor (C-APC, who shared identical HLA class I, but
not class II antigens, with donor B). Proliferation of the CD4
+ cells was measured by CFSE dilution. Data shown are representative of three
independent experiments using three pairs of donors B, C and I. Table 1 provides one example of the HLA class I and class II antigen typing of
individuals B, C, and I used for one of three such experiments.
doi:10.1371/journal.pone.0028948.g003
Table 1. Representative HLA typing of donors used for
experiments demonstrating HLA class I antigen specificity
shown in Figure 3.
Cell type HLA-A HLA-B HLA-DR
A
(CD8
+CD28
2 cells or A-T4
1 1- 1 83 517
B-APC 1284 4 4 1 5 ( 2 )
C-APC 1284 4 3 1 2 ( 5 )
I-APC 24 26 7 61 9 10
The HLA typing of donors for CD8
+ T cells for generation of CD8
+CD28
2
suppressor cells, the priming B-APC cells, the partially matched C-APC cells (which
shared identical HLA-A, -B, but not HLA-DR, with B-APC), or the fully mismatched
I-APC cells (HLA-A, B and DR fully mismatched with B-APC) are shown. Two
additional sets of donors A, B, C, and I were used for repeating this experiment
for a total of three independent times.
doi:10.1371/journal.pone.0028948.t001
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CD8
+CD28
2 T cells
Phenotypic characteristics of CD8
+CD28
2 T cells were
examined before and after donor APCs plus cc cytokine-driven
in vitro expansion to determine if reported markers of CD8 Tregs
such as CTLA-4, FoxP3, CD25, CD56 and CD57 [5,16,17,18,19]
were also expressed by the CD8
+CD28
2 T cells generated by our
protocol. As shown in Figure 6A, among freshly isolated CD8
+ T
cells prior to in vitro stimulation, CD8
+CD28
2 T cells comprised a
small fraction. At baseline, they expressed CD56 (35.0%), CD57
(76.5%), CD62L (28.0%), CD127 (13.6%), and perforin (36.6%),
but exhibited minimal expressions of CTLA-4, FoxP3, CD25
(Figure 6A). Following donor APCs plus cc cytokine-driven
expansion, CD28
2 cells became the predominant population
among CD8
+ cells, and they significantly up-regulated expressions
of CTLA-4 (78.7%), FoxP3 (16.0%), and CD25 (37.5%) compared
with basline, while down-regulated expressions of CD56, CD57,
CD62L, CD127, and perforin (Figure 6B). While the exact
percentages of these markers varied between the CD8
+CD28
2
cells from different individuals (data not shown), the trend of up- or
down-regulations before and after stimulation in cultures
remained the same (1 of 3 representative experiments is shown
in Figure 6).
Discussion
In this study, we reported the novel finding that large numbers
of donor-specific human CD8
+CD28
2 T suppressor cells can be
Figure 5. Cytotoxicity does not contribute to the suppression of proliferation by the in vitro expanded CD8
+CD28
2 T cells. A CFSE
based cytotoxicity assay was set up as follows: target cells were the original priming APCs (for generating the CD8
+CD28
2 T cells) labeled with a high
concentration (2.0 mM) of CFSE (B-APC-CFSE
high), or APCs from an HLA-A, -B, and -DR mismatched indifferent individual labeled with a low
concentration (0.2 mM) of CFSE (I-APC-CFSE
low). A 1:1 mixture of I-APC-CFSE
low and B-APC-CFSE
high cells were plated either by themselves (left panels), or
with the same number of control (CD8
+CD28
+, middle panels) or putative (CD8
+CD28
2, right panels) effector cells in 96 U-bottom plates in triplicates.
At 24, 72, and 120 hr of culture, cells were collected and analyzed by FACS to enumerate CFSE
low and CFSE
high cells. The ratio of cell numbers of I-APC-
CFSE
low over B-APC-CFSE
high was calculated as ‘‘R’’ for all time points. An increase in the value of R indicates specific killing of B-APC-CFSE
high cells by
the effector cells, whereas a stable value of R at 1.0 indicates no specific killing of B-APC-CFSE
high cells by the effector cells. Data shown are
representative of two independent experiments.
doi:10.1371/journal.pone.0028948.g005
Figure 4. Suppression by the in vitro expanded CD8
+CD28
2 T cells is contact dependent but IFN-c or TGF-b independent. Suppression
assays were set up as described in Figure 2 at an S:R ratio of 0.5:1. Proliferation of the CD4
+ cells was measured by CFSE dilution. A, Transwell assays:
the lower chambers of 24-well transwell plates were plated with CFSE-labeled responder cells (3610
5 of R) and stimulator cells (3610
5 of B-APC), and
the in vitro expanded CD8
+CD28
2 T cells were added either in the lower chamber to allow cell-cell contact or in the upper chamber to prevent cell-
cell contact. Data shown are representative of three independent experiments. B, Control suppression without any blocking antibodies. C,
Suppression in the presence of anti-human IFN-c antibody or its isotype control antibody at concentrations of 1 mg/ml, 10 mg/ml and 100 mg/ml. D,
Suppression in the presence of anti-human TGF-b antibody or its isotype control antibody at concentrations of 1 mg/ml, 10 mg/ml and 100 mg/ml.
Data shown for B and C are representative of three independent experiments. Abbreviations used for A–D: ‘‘R’’: CD4
+ responder cells from donor A;
‘‘B-APC’’: APC stimulators from donor B; ‘‘S’’: the in vitro expanded CD8
+CD28
2 T cells.
doi:10.1371/journal.pone.0028948.g004
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cytokines stimulated proliferation. Common cc cytokines IL-2, IL-
7 and IL-15 play critical roles in T cell homeostasis [36]. Recent
reports have demonstrated that IL-15 can promote the generation
and proliferation of CD8
+ memory T cells when stimulated by
anti-CD3 and anti-CD28 antibodies [12,26]. In contrast, a
combination of cc cytokines including IL-2, IL-7 and IL-15 has
been used to expand CD8
+Foxp3
+ Treg in vitro from autoimmune
patients with SLE who have undergone autologous bone marrow
transplant [21]. Human allo-specific CD8
+CD28
2 suppressor T
cells have been reported to be generated by two rounds of
stimulation by allogeneic APCs in which IL-2 was the only
cytokine added during the last four days of cultures [20]. These
cells have been termed as Ts cells. Here, we demonstrated that the
combination of IL-2, IL-7 and IL-15, compared with IL-2 alone,
was superior in inducing significant expansions of allo-specific
CD8
+CD28
2 cells in cultures activated by donor APC stimulation
(Figure 1A, 1B), and that the expanded CD8
+CD28
2 cells were
highly functionally suppressive. The role of each individual
cytokine in the expansion versus inducing the ‘‘suppressive’’
characteristics of this cell population remains to be further
elucidated.
The phenotypic and functional characteristics of the
CD8
+CD28
2 T cells generated in our protocol with a combina-
tion of cc cytokines closely resemble those of previously described
Ts cells [19,20]. They both up-regulate CTLA-4, FoxP3 and
CD25, and have variable degrees of down-regulation of CD62L
during expansion; possess minimal cytotoxicity; and exhibit
suppressive capacity in a contact dependent fashion. We further
demonstrated that our in vitro expanded CD8
+CD28
2 T cells exert
linked suppression of CD4 T cells of a different HLA class II
specificity as long as the HLA class II molecules are co-expressed
with the priming HLA class I molecules on the same APCs. This
has also been previously indirectly demonstrated as a characteristic
of Ts cells [5]. The ability to generate large numbers of
functionally suppressive donor-specific CD8
+CD28
2 T cells that
closely mimic Ts cells with this novel approach of using common
cc cytokines thus has significant potential for facilitating future
clinical use of Treg cell-based immunotherapy for tolerance
induction in transplantation.
Several mechanisms of suppression by CD8 suppressor cells
have been described. These include direct cytotoxicity [37],
secretion of inhibitory cytokines [32,38], down-regulation of co-
stimulatory molecules [5,19], and generation of tolerogenic APCs
[20]. In our suppression assays, the CD8
+CD28
2 T cells
generated by donor APCs plus cc cytokines suppress proliferation
of CD4
+ T cells in a donor-specific and dose-dependent manner.
Interestingly, distinct from CD4 Treg cells, the CD8
+CD28
2 T
cells do not have the ability to suppress proliferation driven by
non-specific stimulation by anti-CD3 and anti-CD28 coated
Dynabeads. This finding indicates the importance of the
interacting APCs in mediating the suppression by the
CD8
+CD28
2 T cells. Further studies characterizing phenotypic
and functional changes of the interacting APCs will provide
definitive evidence for this hypothesis. Furthermore, the transwell
assay showed that separation of the CD8
+CD28
2 T cells alone or
CD8
+CD28
2 T cells together with stimulator APCs from the
responder CD4
+ T cells abolished the ability of the CD8
+CD28
2
T cells to suppress. These data further indicate that suppression of
CD8
+CD28
2 T cells is mediated through cell-cell contact in a
Figure 6. Phenotypic characteristics of the in vitro expanded CD8
+CD28
2 T cells. CD8
+ T cells freshly isolated from healthy volunteers (A)o r
after in vitro stimulation with donor APCs plus cc cytokines for 9 days (B) were analyzed for cell surface or intracellular markers by multichromatic flow
cytometry. Date shown are representative of three independent experiments.
doi:10.1371/journal.pone.0028948.g006
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+CD28
2 T cells
and the APCs, but also between the APCs (or the CD8
+CD28
2 T
cells) and the responding CD4
+ T cells.
The finding that suppression by the CD8
+CD28
2 T cells is
restricted by HLA class I but is promiscuous towards HLA class II
specificities with which the responding CD4 TCRs interact
suggests a potential mechanism for linked suppression. Linked
suppression classically depicts a situation in which co-expression of
an indifferent antigen and a tolerant antigen on the same graft
allows acceptance of the indifferent antigen in a host previously
tolerized to the tolerant antigen [39]. Dendritic cells are thought to
play a critical role in the process of linked suppression [39]. In our
studies, C-APC cells co-express both matched HLA class I antigens
with the priming donor B-APC and mismatched HLA class II
antigens with the priming donor B-APC. Therefore linked
suppression by the CD8
+CD28
2 T cells occurs via C-APC cells,
and proliferation of CD4
+ responder to the mismatched class II
antigens is suppressed. These findings have significant implications
for designing and understanding the therapeutic value of this
CD8
+ suppressor population.
The role of cytotoxicity in mechanisms of regulation by CD8
+
suppressor cells has been debated. Suppressive CD8
+CD28
2 Ts
cells generated by repeated stimulations with alloantigens have
been shown to have no cytotoxicity towards the stimulating
allogeneic APCs [5]. In contrast, Zheng et al [37] reported that
human CD8
high T cells induced by allogeneic CD40-activated B
cells have regulatory property that is at least in part mediated
through cytotoxicity towards the allogeneic priming PBMC. In our
in vitro CFSE-based cytotoxicity assay (Figure 5), it appears that the
CD8
+CD28
2 T cells generated by our protocol do not possess
strong cytotoxicity towards their priming APCs. This is consistent
with the down-regulation of perforin in these cells after culturing
(Figure 6). It should be noted, however, that cytotoxicity and other
possible regulatory mechanisms, such as cytokine production or
those mediated through high levels of expression of FoxP3 and
CTLA-4, need not be mutually exclusive.
Both cytokine TGF-b [13,29,30] and IFN-c [8,31,32] have
been implicated in the regulatory mechanisms of CD8
+ suppressor
cells in different studies. In our system, neither anti-IFN-c nor
anti-TGF-b antibody reversed the suppressive effect of the
expanded CD8
+CD28
2 T cells (Figure 4C, D). CD56 and CD57
are two markers of natural killer cells previously reported to over-
express on CD8
+CD28
2 Ts cells [19]. However, in our culture
system the expression of these markers on the CD8
+CD28
2 cells
decreased after culture, suggesting that they may not play a major
role in the functionality of expanded CD8
+CD28
2 cells in our
system.
Two proteins, FoxP3 and CTLA-4, are discernibly up-regulated
in the expanded CD8
+CD28
2 T cells. FoxP3 has been described
as an important marker for CD8
+ suppressor cells in humans
[18,20,40,41]. However, unlike in mice, in humans non-regulatory
T cells including effector cells can also up-regulate FoxP3
expression transiently upon activation [42,43]. Moreover, there
are also CD8
+ suppressor cells that are not characterized with
FoxP3 expression [16,32,38]. Whether or not FoxP3 up-regulation
in our in vitro expanded CD8
+CD28
2 T cells contribute to their
suppressive function remains to be elucidated. CTLA-4 is another
marker described in CD8
+ suppressor cells [18,20,40,41]. CTLA-4
is a homologue of CD28, and is known as a negative co-
stimulatory receptor which upon signaling from CD80 and CD86
delivers inhibitory signals to T cells to down-regulate T cell
activation [44,45]. Recent data also suggest that signaling between
CTLA-4 and CD80/CD86 can be bi-directional. CTLA-4
expressed on surface of CD4
+ Tregs has been shown to interact
with CD80/CD86 expressed on APCs and subsequently down-
regulate their expression, possibly via a process of trans-
endocytosis [46], thereby decreasing the ability of APCs to
stimulate T cells through CD28 [47,48]. CTLA-4 has also been
reported to up-regulate indolamine 2,3 dioxygenase (IDO) in some
subsets of APCs as yet another mechanism for regulating T cell
responses [49]. Given the profound up-regulation of this molecule
(from 0.2% to 78.7%, Figure 6) and simultaneous down-regulation
of CD28 in our CD8
+CD28
2 T cells, CTLA-4 mediated negative
signaling to the interacting APCs is a highly attractive potential
mechanism of suppression by this cell population.
While robust suppression is observed from our in vitro expanded
CD8
+CD28
2 T cells, an important issue which remains to be
resolved is how these cells would behave in vivo upon adoptive
transfer. Significant plasticity has been described of
CD4
+CD25
+FoxP3
+ T cells. Studies of in vivo viability, stability
and functionality of the expanded human CD8
+CD28
2 T cells in
our protocol will necessitate the use of functional humanized
mouse models of allogeneic immune responses. Such studies are
critical before this approach can be safely translated into clinical
applications and are currently being actively pursued in our
laboratory.
In conclusion, our findings show that donor APCs plus cc
cytokines can be harnessed for efficient in vitro expansion of human
donor-specific CD8
+CD28
2 T suppressor cells in a simple and
robust culture system. This approach may hold promise for clinical
application of using regulatory T cell-based immunotherapy for
tolerance induction in transplantation in the future.
Materials and Methods
Ethics Statement
This study was approved by the Northwestern Institutional
Review Board and written consent was obtained from the
participants.
Human subjects and HLA typing
Peripheral blood mononuclear cells (PBMCs) were obtained
from healthy volunteers. HLA typing was performed by the
Northwestern Histocompatibility Laboratory using molecular
methods. Donors for T cells and APCs were selected for their
HLA- A, B and DR compatibility or incompatibility based on the
specific requirements of individual experiments.
Isolation of PBMCs and cell subsets
PBMCs were isolated from fresh whole blood using Lymphocyte
Separation Medium (Mediatech Inc., Manassas, VA) by density
gradient centrifugation. CD8
+ and CD4
+ T cells were purified
from PBMCs using CD8 or CD4 isolation kits (Miltenyi Biotec)
through positive selection according to the manufacturer’s
protocols. Purities for both T cells were confirmed by flow
cytometry and were routinely .98%. APCs were isolated from
PBMCs by depletion of CD3
+ cells using CD3 microbeads
(Miltenyi Biotech). After culturing of the CD8
+ cells for indicated
number of days, CD28
+ cells were removed by positive selection
using human CD28 MicroBead Kit (Miltenyi Biotech, puri-
ty.99%), and the flow-through was collected as CD28
2 cells
(purity.95%). Again, purity of all isolated cells was confirmed by
flow cytometry.
In vitro generation and expansion of CD8
+CD28
2 cells
with allogeneic APCs and cc cytokines
2610
6 purified CD8
+ T cells from individual A were cultured
with 1610
6 HLA-A, -B, -DR mismatched APCs from individual B
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normal human blood group AB serum, 2 mM L-glutamine,
10 mM HEPES and 16antibiotic-antimycotic solution; all from
Gibco-BRL, Gaithersburg, MD) supplemented with IL-2 (20 U/
ml), IL-7 (50 ng/ml) and IL-15 (50 ng/ml) (PeproTech Inc.,
Rocky Hill, NJ) in 24-well plates at 37uCi n5 %C O 2.
Supplemented culture medium was changed on days 4, 7 and 8
(by replacing 1 ml of the culture medium with fresh medium
containing cytokines). Cells in each well were split into two wells
on day 6 and harvested on day 9, and the CD28
2 population was
isolated as described above.
Suppression of donor-specific proliferation by in vitro
generated CD8
+CD28
2 cells
5610
4 CFSE labeled purified CD4
+ T cells from individual A
(A-T4) were used as ‘‘responders (R)’’ and stimulated with 5610
4
APCs from the original priming donor (individual B; B-APC). APCs
from an HLA-A,-B,-DR complete-mismatched indifferent donor
(I-APC)o r1 610
4 anti-CD3/anti-CD28 Dynabeads (Invitrogen,
Carlsbad, CA) were used as third party or non-specific stimulation
controls respectively. All cultures were prepared in triplicates and
incubated in 96-well U-bottom plates in 37uC5 %C O 2 incubator.
The CD8
+CD28
2 cells were added as ‘‘suppressor (S)’’ at S:R
ratios of 0.5:1, 0.1:1 and 0.02:1 (the cell number of ‘‘R’’ was kept
constant). CFSE dilution was assessed on day 7 to determine
extent of proliferation. In selected experiments, anti-human IFN-c
(eBioscience Inc.), anti-human TGF-b antibody (BioXcell, West
Lebanon, NH), or respective isotype controls were added to
cultures at concentrations of 1 mg/ml, 10 mg/ml or 100 mg/ml.
Parallel cultures were analyzed using
3H-thymidine incorporation.
1 mCi
3H-thymidine (PerkinElmer, San Jose, CA) was added per
well for the last 18 hrs of a 7-day culture, and incorporated
radioactivity was measured as counts per minute (CPM) with a
Perkin-Elmer scintillation counter.
Transwell experiments
The lower chambers of 24-well transwell plates were plated with
either 3610
5 CFSE labeled naı ¨ve CD4
+ T cells from individual A
(A-T4), or with A-T4 and 3610
5 priming APCs from individual B
(B-APC) in the presence or absence of 3610
4 CD8
+CD28
2 cells
(total volume 600 ml). The upper chambers were plated with
medium only, CD8
+CD28
2 cells only, or CD8
+CD28
2 cells plus
priming APCs (B-APC). Cells collected from the lower chamber
after 7 days of culture were assessed by FACS for CFSE dilution.
Cytotoxicity by CD8
+CD28
2 cells
CFSE-based cytotoxic assay was set up according to published
methods [33] as follows. APCs serving as target cells were labeled
with two concentrations of CFSE: high concentration (2.0 mM) for
APCs from the priming donor (B-APC-CFSE
high) and low
concentration (0.2 mM) for APCs from an HLA-A,-B,-DR
complete-mismatched indifferent donor (I-APC-CFSE
low). The in
vitro generated CD8
+CD28
2 cells or their CD8
+CD28
+ counter-
part were used as putative or control effector cells respectively.
5610
4 effector cells were cultured with 5610
4 each of B-APC-
CFSE
high and I-APC-CFSE
low together in 96-well U-bottom plates
in triplicate wells. Cultured B-APC-CFSE
high and I-APC-CFSE
low in
the absence of effector cells were used as controls for spontaneous
cytolysis. B-APC-CFSE
high and I-APC-CFSE
low were enumerated by
FACS after 0, 24, 72 and 120 hrs of culture. The ratios of cell
numbers of I-APC-CFSE
low over B-APC-CFSE
high in the absence or
the presence of effector cells were calculated over time to estimate
specific killing of B-APC-CFSE
high.
Multi-color flow cytometric analysis
The following anti-human antibodies and their isotype controls
were used: FITC conjugated anti-CD3 (OKT3), CD4(OKT4),
CD8(SK1), CD56(MEM188), CD57(TBO1), CD62L(DREG56),
CD127(RDR5), Perforin(dG9), all from eBioscience; FITC conju-
gated anti-human CTLA-4(A3.4H2.H12, Cedarlane USA, Bur-
lington, NC), CD25(BC96), Granzyme B(GB11, Biolegend, San
Diego, CA); PE conjugated anti-human Foxp3(eBioscience, San
Diego, CA); ECD conjugated anti-human CD8(SFCI21Thy2D3),
PE-cyanin 5 (PC5) conjugated anti-human CD28(28.2), PE-cyanin
7 (PC7) conjugated anti-human CD8(SFCI21Thy2D3, Beckman
Coulter, Miami, FL). Surface and intra-cellular staining was
performed following manufacturers’ recommended protocols. Data
was acquired on a 5-color FC500 flow cytometer and analyzed
using the CXP program (Beckman-Coulter).
Statistical analysis
Comparisons were made by paired Student’s t test. Differences
were considered significant if the P value was ,0.05.
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